← Search & browse all drugs

chloropyramine

R06AC03

Forms & Strengths

Tablets 2 mg
Tablets 4 mg
Syrup 0.5 mg/mL
Injectable solution 10 mg/mL

Adult Dosing

Allergic rhinitis/urticaria: 4 mg PO 2‑3 times daily (max 12 mg/day)
Severe pruritus: 6‑8 mg PO 3 times daily (max 24 mg/day)
Acute anaphylaxis adjunct: 10 mg IV/IM single dose, repeat after 30 min if needed

Pediatric Dosing

>1 yr: 0.5 mg/kg PO 2‑3 times daily (max 6 mg/day)
6‑12 yr: 1‑2 mg PO 2‑3 times daily
<1 yr: not recommended

Indications

Seasonal and perennial allergic rhinitis
Acute and chronic urticaria
Allergic conjunctivitis
Pruritic dermatoses (e.g., insect bites)
Mild‑moderate anaphylactic reactions (adjunct therapy)
Angioedema

Mechanism of Action

Competitive reversible H1‑receptor antagonist
Blocks peripheral and central histamine actions
Exhibits anticholinergic and sedative activity due to CNS penetration

Contraindications

Hypersensitivity to chloropyramine or other first‑generation antihistamines
Narrow‑angle glaucoma
Severe hepatic or renal impairment
Neonates and infants <6 months
Pregnancy category C – avoid unless benefit outweighs risk

Adverse Reactions

Sedation and somnolence
Dry mouth (xerostomia)
Constipation or gastrointestinal upset
Urinary retention, especially in men with BPH
Blurred vision, mydriasis
Tachycardia or palpitations
Hypotension
Skin rash or photosensitivity
Rare extrapyramidal symptoms

Drug Interactions

Additive CNS depression with alcohol, opioids, benzodiazepines, barbiturates, other antihistamines
Increased anticholinergic effects with anticholinergic drugs (e.g., tricyclic antidepressants, atropine)
Cimetidine may raise chloropyramine plasma levels
MAO inhibitors may potentiate anticholinergic and sedative effects
Concurrent QT‑prolonging agents – monitor cardiac rhythm
Avoid simultaneous use with other H1 antagonists to prevent overdose

Curated Content: Needs Vetting Before Put to Clinical Use